In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …

Background Bortezomib, thalidomide, and dexamethasone (VTd) plus autologous stem-cell
transplantation is standard treatment in Europe for transplant-eligible patients with newly …

It is clear that cancers comprise a mixture of clones, a feature termed intra‐clonal
heterogeneity, that compete for spatial and nutritional resources in a fashion that leads to …

Autologous stem cell transplantation (ASCT) has been the mainstay of multiple myeloma
(MM) treatment for approximately 30 years. Although the continuous introduction of novel …

PURPOSE To address the role of consolidation treatment for newly diagnosed, transplant
eligible patients with multiple myeloma in a controlled clinical trial. PATIENTS AND …

Achieving complete remission (CR) in multiple myeloma (MM) translates into extended
survival, but two subgroups of patients fall outside this paradigm: cases with unsustained …

Background In part 1 of the two-part CASSIOPEIA study, treatment before and after
autologous haematopoietic stem-cell transplantation (HSCT) with daratumumab plus …

This multicenter phase 2 study of the European Myeloma Network investigated the
combination of carfilzomib, thalidomide, and dexamethasone (KTd) as induction …

A prospective continuous survey would be the ideal next step in assessing the present and
future impact of the European Curriculum on hematology training in Europe. If implemented …

There have been major advances in the past decade in the continuum of therapy for
transplantation-eligible multiple myeloma patients. For patients requiring therapy …